Log In
BCIQ
Print this Print this
 

RetnaGene AMD test

  Manage Alerts
Collapse Summary General Information
Company Laboratory Corp. of America Holdings
DescriptionTest to assess the risk of developing choriodal neovascularization (CNV)
Molecular Target Not applicable
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationOphthalmic, Diagnostic
Indication DetailsAssess the risk of choroidal neovascularization (CNV); Predict the genetic risk of a patient with dry or early stage age-related macular degeneration (AMD)
Regulatory Designation
PartnerValeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$322.0M

$312.0M

$10.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/07/2016

$302.0M

$302.0M

0

11/17/2014

$20.0M

$10.0M

$10.0M

Get a free BioCentury trial today